- Home
- MGNX vs KNOP Comparison
MGNX vs KNOP Comparison
Compare MGNX & KNOP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- KNOP
- Stock Information
- Founded
- MGNX 2000
- KNOP 2013
- Country
- MGNX United States
- KNOP United Kingdom
- Employees
- MGNX N/A
- KNOP N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- KNOP Marine Transportation
- Sector
- MGNX Health Care
- KNOP Consumer Discretionary
- Exchange
- MGNX Nasdaq
- KNOP Nasdaq
- Market Cap
- MGNX 257.3M
- KNOP 235.1M
- IPO Year
- MGNX 2013
- KNOP 2013
- Fundamental
- Price
- MGNX $3.24
- KNOP $6.11
- Analyst Decision
- MGNX Buy
- KNOP
- Analyst Count
- MGNX 11
- KNOP 0
- Target Price
- MGNX $8.57
- KNOP N/A
- AVG Volume (30 Days)
- MGNX 770.4K
- KNOP 57.3K
- Earning Date
- MGNX 11-05-2024
- KNOP 12-04-2024
- Dividend Yield
- MGNX N/A
- KNOP 1.71%
- EPS Growth
- MGNX N/A
- KNOP N/A
- EPS
- MGNX N/A
- KNOP N/A
- Revenue
- MGNX $141,329,000.00
- KNOP $296,181,000.00
- Revenue This Year
- MGNX $119.63
- KNOP $6.70
- Revenue Next Year
- MGNX N/A
- KNOP $2.79
- P/E Ratio
- MGNX N/A
- KNOP N/A
- Revenue Growth
- MGNX 16.68
- KNOP 5.27
- 52 Week Low
- MGNX $2.95
- KNOP $4.94
- 52 Week High
- MGNX $21.88
- KNOP $9.11
- Technical
- Relative Strength Index (RSI)
- MGNX 37.79
- KNOP 45.58
- Support Level
- MGNX $3.61
- KNOP $5.90
- Resistance Level
- MGNX $5.10
- KNOP $6.32
- Average True Range (ATR)
- MGNX 0.35
- KNOP 0.17
- MACD
- MGNX -0.10
- KNOP 0.04
- Stochastic Oscillator
- MGNX 4.62
- KNOP 54.35
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).
About KNOP KNOT Offshore Partners LP Common Units representing Limited Partner Interests
KNOT Offshore Partners LP owns, operates, and shuttles tankers under long-term charters in the North Sea and Brazil. The company provides crude oil loading, transportation, and storage services under time charters and bareboat charters. The Partnership is formed for acquiring ownership interests in over four shuttle tankers owned by Knutsen NYK Offshore Tankers AS (KNOT). It operates through the shuttle tanker market segment.